Immunomodulatory Cell Therapy Using αGalCer-Pulsed Dendritic Cells Ameliorates Heart Failure in a Murine Dilated Cardiomyopathy Model. (21st October 2022)

• Record Type: Journal Article
• Authors: Ikeda, Masataka; Ide, Tomomi; Matsushima, Shouji; Ikeda, Soichiro; Okabe, Kosuke; Ishikita, Akihito; Tadokoro, Tomonori; Sada, Masashi; Abe, Ko; Sato, Midori; Hanada, Akiko; Arai, Shinobu; Ohtani, Kisho; Nonami, Atsushi; Mizuno, Shinichi; Morimoto, Sachio; Motohashi, Shinichiro; Akashi, Koichi; Taniguchi, Masaru; Tsutsui, Hiroyuki
• Is Part Of: Circulation. Volume 15:Number 12(2022)
• Page Start: e009366
• Publication Date: 2022-10-21
• Subjects: α-galactosylceramide-pulsed dendritic cell -- chronic heart failure -- dilated cardiomyopathy -- immune system -- natural killer T cell; Heart failure -- Periodicals; 616.129005
• DOI: 10.1161/CIRCHEARTFAILURE.122.009366
• Languages: English
• ISSNs: 1941-3289

Abstract

Abstract : Background: Dilated cardiomyopathy (DCM) is a life-threatening disease, resulting in refractory heart failure. An immune disorder underlies the pathophysiology associated with heart failure progression. Invariant natural killer T (iNKT) cell activation is a prospective therapeutic strategy for ischemic heart disease. However, its efficacy in nonischemic cardiomyopathy, such as DCM, remains to be elucidated, and the feasible modality for iNKT cell activation in humans is yet to be validated. Methods: Dendritic cells isolated from human volunteers were pulsed with α-galactosylceramide ex vivo, which were used as α-galactosylceramide-pulsed dendritic cells (αGCDCs). We treated DCM mice harboring mutated troponin T ΔK210/ΔK210 with αGCDCs and evaluated the efficacy of iNKT cell activation on heart failure in DCM mice. Furthermore, we investigated the molecular basis underlying its therapeutic effects in these mice and analyzed primary cardiac cells under iNKT cell-secreted cytokines. Results: The number of iNKT cells in the spleens of DCM mice was reduced compared with that in wild-type mice, whereas αGCDC treatment activated iNKT cells, prolonged survival of DCM mice, and prevented decline in the left ventricular ejection fraction for 4 weeks, accompanied by suppressed interstitial fibrosis. Mechanistically, αGCDC treatment suppressed TGF (transforming growth factor)-β signaling and expression of fibrotic genes and restored vasculature that was impaired in DCM hearts by upregulating angiopoietin 1 ( Angpt1 ) expression. Consistently, IFNγ (interferon gamma) suppressed TGF-β-induced Smad2/3 signaling and the expression of fibrotic genes in cardiac fibroblasts and upregulated Angpt1 expression in cardiomyocytes via Stat1. Conclusions: Immunomodulatory cell therapy with αGCDCs is a novel therapeutic strategy for heart failure in DCM.